Share on LinkedInShare on LinkedIn

ARTICLE · 02 FEBRUARY 2015

Doubling Down: The New Focus For Pharma

This week we thought it would be interesting to share insights on a topical issue from Deloitte's U.S. Center for Health Solutions. This "My Take" from the January 20th, 2015 Health Care Current written by Homi Kapadia, Vice Chairman, U.S Life Sciences Leader, Deloitte LLP, provides a view on the rise of "pure play" business strategies for life science companies

United KingdomGovernment, Public Sector

This week we thought it would be interesting to share insights on a topical issue from Deloitte's U.S. Center for Health Solutions. This "My Take" from the January 20th, 2015 Health Care Current written by Homi Kapadia, Vice Chairman, U.S Life Sciences Leader, Deloitte LLP, provides a view on the rise of "pure play" business strategies for life science companies.1

Steve Jobs was said to have built his career around the mantra of focus and simplicity. Both are important for companies in any industry. While the life sciences sector seems to be in a perpetual state of change and adaptation, one trend over the past year or so has caught my eye. And it pertains to exactly that: focus and simplicity versus breadth and portfolio diversity.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from